

**Company News  
Press Release**



For Immediate Release  
January 12, 2015

Contact: **Diane Frankenfield**  
Leerink Partners  
(617) 918-4850  
[diane.frankenfield@leerink.com](mailto:diane.frankenfield@leerink.com)

Contact: **Chris Kittredge/Patrick Scanlan**  
Sard Verbinnen & Co.  
(212) 687-8080  
[CKittredge@SARDVERB.com](mailto:CKittredge@SARDVERB.com)

**LEERINK PARTNERS NAMES JAMES BOYLAN PRESIDENT**

BOSTON—January 12, 2015—Leerink Partners, a leading healthcare investment bank, today announced that James Boylan has been appointed President. Mr. Boylan will retain the title of Head of Investment Banking and will oversee Sales and Trading. Mr. Boylan has served on Leerink’s management committee since 2009. He will continue to be based out of New York.

“Jim has been a driving force behind the growth and success of Leerink Partners’ investment banking franchise over the past five years,” said Jeff Leerink, Chairman and CEO of Leerink Partners. “Under Jim’s leadership our investment banking business has developed a highly effective, client-centric organization that is recognized as a market leader in healthcare equity financing and a skilled M&A advisor. Jim has provided the vision and the leadership to advance our firm’s position and our ability to be an impactful partner for our clients. His appointment is also a reflection of Leerink’s commitment to driving growth initiatives planned for 2015 and beyond.”

Over the five years Mr. Boylan has lead the investment banking business Leerink has bookrun more than 100 transactions, raising more than \$8.5B in capital for its clients. In 2014, Leerink continued to strengthen its position as a leading healthcare underwriter, having achieved a record 35 bookrun financings, including 18 initial public offerings. This represents an increase of 34 percent from 2013, its previous record year. In addition, Leerink has substantially grown its M&A strategic advisory business – advising on 48 transactions since 2010 and most recently serving as co-advisor to NPS Pharmaceuticals on its recently announced \$5.2B sale to Shire PLC.

Henri Termeer, former CEO, Chairman and President of Genzyme Corporation, and member of the Leerink Advisory Committee commented “Jim has consistently demonstrated an ability to both set and execute on a strategic plan for the growth of the investment banking business at Leerink – his influence has been a great contributor to the elevation of Leerink’s profile in the healthcare advisory business.”

Mr. Boylan has 20 years of experience in healthcare investment banking. Prior to joining Leerink in 2009 as a Senior Managing Director and Head of Investment Banking, Mr. Boylan was a Managing Director at Merrill Lynch for over a decade working with healthcare companies to originate and execute merger & acquisition transactions and equity and convertible underwritings. At Leerink Partners, Mr. Boylan continues to work with and advise innovative and growth oriented healthcare companies on M&A and capital formation strategies and transactions.

Mr. Boylan earned his MBA from Columbia University in 1994 and a B.S. from Lehigh University in 1989.

**About Leerink Partners, LLC**

Leerink Partners LLC is a leading investment bank, specializing in healthcare. Our knowledge, experience and focus enable us to help our clients define and achieve their strategic, capital markets and investment objectives. We partner with companies that develop and commercialize innovative products and services that are defining the future of healthcare. Leerink Partners LLC is a member of FINR/SIPC. For more information, please visit: [www.leerink.com](http://www.leerink.com).